The HERACLES-A (HER2 Amplification for Colo-Rectal Cancer Enhanced Stratification) was the first large phase II clinical trial testing weekly trastuzumab plus daily lapatinib in HER2 positive KRAS exon 2 wild type aCRC patients who proved to be refractory to standard-of-care therapy, including cetuximab. The gene discussed is ERBB2; the disease is rectal cancer.